Selumetinib (AZD6244)

For research use only. Not for use in humans.

目录号：S1008 别名： ARRY-142886 中文名称：司美替尼

Selumetinib (AZD6244) Chemical Structure

CAS No. 606143-52-6

Selumetinib (AZD6244, ARRY-142886)是一种有效，高选择性的MEK抑制剂，对MEK1的IC50为14 nM，对MEK2的Kd值为530 nM。它也抑制ERK1/2磷c酸化，IC50为10 nM，对p38α， MKK6， EGFR， ErbB2， ERK2， B-Raf等没有抑制作用。Selumetinib可抑制细胞增殖、迁移并诱导凋亡。Phase 3。

规格

价格

库存

购买数量

10mM (1mL in DMSO)	RMB 956.17	现货
50mg	RMB 741.25	现货
200mg	RMB 1395.14	现货
500mg	RMB 3011.75	现货
大包装	有超大折扣

大剂量询单有大折扣!

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834 | Email：info@selleck.cn

客户使用Selleck生产的Selumetinib (AZD6244)发表文献526篇：

Nature, 2020, 588(7838):509-514

PubMed: 32927473 ( click the link to review the publication )

Cancer Cell, 2020, 37(1):85-103

PubMed: 31935375 ( click the link to review the publication )

Cancer Cell, 2020, 13;37(1):104-122e12

PubMed: 31935369 ( click the link to review the publication )

Cancer Cell, 2020, 37(2):183-199

PubMed: 31978326 ( click the link to review the publication )

Nat Med, 2019, 25(1):130-140

PubMed: 30510251 ( click the link to review the publication )

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Nat Mater, 2018, 17(4):361-368

PubMed: 29403054 ( click the link to review the publication )

Nat Med, 2018, 24(7):968-977

PubMed: 29808010 ( click the link to review the publication )

Nat Med, 2018, 24(7):954-960

PubMed: 29808009 ( click the link to review the publication )

Cell, 2018, 172(4):857-868

PubMed: 29336889 ( click the link to review the publication )

Nat Med, 2018, 24(7):961-967

PubMed: 29808006 ( click the link to review the publication )

Cancer Cell, 2018, 33(1):91-107

PubMed: 29316436 ( click the link to review the publication )

Cancer Cell, 2018, 34(3):439-452

PubMed: 30205046 ( click the link to review the publication )

Nat Chem Biol, 2017, 13(1):119-126

PubMed: 27870838 ( click the link to review the publication )

Gastroenterology, 2017, 152(5):1161-1173

PubMed: 27956228 ( click the link to review the publication )

Nature, 2016, 10.1038/nature19347

PubMed: 27580028 ( click the link to review the publication )

Nat Biotechnol, 2016, 34(2):184-191

PubMed: 26780180 ( click the link to review the publication )

Gastroenterology, 2016, 150(4):918-30

PubMed: 26677984 ( click the link to review the publication )

Nat Med, 2015, 21(9):1038-47

PubMed: 26301689 ( click the link to review the publication )

Nat Genet, 2015, 47(9):996-1002

PubMed: 26214590 ( click the link to review the publication )

Cancer Discov, 2015, 5(3):264-73

PubMed: 25542447 ( click the link to review the publication )

Cancer Discov, 2015, 5(4):358-67

PubMed: 25673644 ( click the link to review the publication )

Cancer Cell, 2015, 27(2):240-56

PubMed: 25600339 ( click the link to review the publication )
Nature, 2014, 30;514(7524):628-32.

PubMed: 25119024 ( click the link to review the publication )

Cancer Discov, 2014, 4(1):94-109

PubMed: 24265153 ( click the link to review the publication )

Cancer Discov, 2014, 4(1):69-79

PubMed: 24265152 ( click the link to review the publication )

Cancer Discov, 2014, 4(10):1214-29

PubMed: 25256614 ( click the link to review the publication )

Cancer Discov, 2013, 4(2):232-45

PubMed: 24356096 ( click the link to review the publication )

Cancer Discov, 2013, 3(3):350-62

PubMed: 23288408 ( click the link to review the publication )

Nature, 2012, 26;487(7408):505-9.

PubMed: 22763448 ( click the link to review the publication )

Cell, 2012, 21;151(5):937-50.

PubMed: 23178117 ( click the link to review the publication )

Cancer Discov, 2012, 2(5):414-24

PubMed: 22588879 ( click the link to review the publication )

Cancer Discov, 2012, 2(11):1036-47

PubMed: 22915752 ( click the link to review the publication )

Nat Chem Biol, 2012, 8(11):905-912

PubMed: 23023260 ( click the link to review the publication )

Nat Genet, 2011, 44(2):133-9

PubMed: 22197931 ( click the link to review the publication )

Nat Genet, 2011, 43(11):1119-26

PubMed: 21946352 ( click the link to review the publication )

Nature, 2010, 16;468(7326):968-72.

PubMed: 21107320 ( click the link to review the publication )

Cancer Res, 2021, canres.1895.2020

PubMed: 33402388 ( click the link to review the publication )

Cancer Lett, 2021, 502:25-33

PubMed: 33440231 ( click the link to review the publication )

J Exp Clin Cancer Res, 2021, 40(1):22

PubMed: 33413561 ( click the link to review the publication )

Drug Metab Dispos, 2021, 49(1):53-61

PubMed: 33148688 ( click the link to review the publication )

Nat Commun, 2020, 11(1):3157

PubMed: 32572029 ( click the link to review the publication )

Eur Respir J, 2020, 8;2000522

PubMed: 32513782 ( click the link to review the publication )

Sci Adv, 2020, 22;6(21):eaaz8521

PubMed: 32494745 ( click the link to review the publication )

Dev Cell, 2020, 52(5):563-573

PubMed: 32032547 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2020, 117(33):20004-20014

PubMed: 32747568 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2020, 202008017

PubMed: 32989154 ( click the link to review the publication )
Genome Med, 2020, 18;12(1):17

PubMed: 32070411 ( click the link to review the publication )

Cancer Res, 2020, canres.0448.2020

PubMed: 32605999 ( click the link to review the publication )

Cell Rep, 2020, 31(2):107514

PubMed: 32294432 ( click the link to review the publication )

Eur J Cancer, 2020, 144:17-30

PubMed: 33316635 ( click the link to review the publication )

Oncogene, 2020, 14

PubMed: 32291414 ( click the link to review the publication )

Oncogene, 2020, 39(20):4132-4154

PubMed: 32238882 ( click the link to review the publication )

Oncogene, 2020, 39(15):3218-3225

PubMed: 32051554 ( click the link to review the publication )

Oncogene, 2020, 39(3):703-717

PubMed: 31541192 ( click the link to review the publication )

J Invest Dermatol, 2020, 3 pii: S0022-202X(20)31407-X

PubMed: 32376279 ( click the link to review the publication )

Cancers (Basel), 2020, 12(9)E2586

PubMed: 32927828 ( click the link to review the publication )

Cancers (Basel), 2020, 27;12(5)pii: E1087

PubMed: 32349331 ( click the link to review the publication )

Cancers (Basel), 2020, 13;12(2) pii: E436

PubMed: 32069833 ( click the link to review the publication )

Cancers (Basel), 2020, 12(7):E1744

PubMed: 32629964 ( click the link to review the publication )

PLoS Pathog, 2020, 16(2):e1008307

PubMed: 32069328 ( click the link to review the publication )

Cell Death Dis, 2020, 29;11(5):406

PubMed: 32471991 ( click the link to review the publication )

Br J Cancer, 2020, 22

PubMed: 32439932 ( click the link to review the publication )

FASEB J, 2020, 10.1096/fj.202000657R

PubMed: 33124742 ( click the link to review the publication )

Front Immunol, 2020, 14;11:867

PubMed: 32477351 ( click the link to review the publication )

Cancer Discov, 2020, CD-20-0706

PubMed: 33208393 ( click the link to review the publication )

Development, 2020, 147(23)dev192351

PubMed: 33144395 ( click the link to review the publication )

Mol Cancer Ther, 2020, 13;molcanther11722019

PubMed: 32404410 ( click the link to review the publication )

Mol Oncol, 2020, 26

PubMed: 32336009 ( click the link to review the publication )

Aging (Albany NY), 2020, 7;12(9):8221-8240

PubMed: 32379705 ( click the link to review the publication )

Mol Cancer Res, 2020, 10.1158/1541-7786.MCR-20-0664

PubMed: 33106373 ( click the link to review the publication )
Front Oncol, 2020, 10:1482

PubMed: 33042794 ( click the link to review the publication )

Int J Mol Sci, 2020, 21(20)E7649

PubMed: 33081092 ( click the link to review the publication )

Int J Mol Sci, 2020, 18;21(8):2825

PubMed: 32325639 ( click the link to review the publication )

Sci Rep, 2020, 10(1):21985

PubMed: 33319783 ( click the link to review the publication )

J Biol Chem, 2020, 30 pii: jbc

PubMed: 32358059 ( click the link to review the publication )

Cancer Commun (Lond), 2020, 10.1002/cac2.12092

PubMed: 32888253 ( click the link to review the publication )

J Ethnopharmacol, 2020, 251:112535

PubMed: 31926315 ( click the link to review the publication )

Chem Biol Interact, 2020, 315:108910

PubMed: 31790661 ( click the link to review the publication )

Transl Oncol, 2020, 14(1):100920

PubMed: 33137541 ( click the link to review the publication )

Eur J Pharmacol, 2020, 870:172821

PubMed: 31770526 ( click the link to review the publication )

Pediatr Blood Cancer, 2020, e28639

PubMed: 32975370 ( click the link to review the publication )

Pathol Oncol Res, 2020, 10.1007/s12253-020-00834-y

PubMed: 32591993 ( click the link to review the publication )

J Chemother, 2020, 32(8):437-444

PubMed: 33052075 ( click the link to review the publication )

Front Cell Dev Biol, 2020, 8:610

PubMed: 32754596 ( click the link to review the publication )

Cell Mol Life Sci, 2020, 10.1007/s00018-020-03617-5

PubMed: 32804243 ( click the link to review the publication )

Commun Biol, 2020, 3(1):593

PubMed: 33087841 ( click the link to review the publication )

bioRxiv, 2020, 2020/9/20.4.7.30734

PubMed: 32511305 ( click the link to review the publication )

Mol Cancer Res, 2020, 18(4):537-548

PubMed: 31911540 ( click the link to review the publication )

Sci Rep, 2020, 10(1):13124

PubMed: 32753665 ( click the link to review the publication )

J Pathol, 2020, e5503

PubMed: 32613636 ( click the link to review the publication )

Cell Mol Gastroenterol Hepatol, 2020, S2352-345X(20)30117-X

PubMed: 32771388 ( click the link to review the publication )

Nat Chem Biol, 2020, 10.1038/s41589-020-0609-7

PubMed: 32778845 ( click the link to review the publication )

Mol Oncol, 2020, 10.1002/1878-0261.12673

PubMed: 32191822 ( click the link to review the publication )

Cancer Cell, 2020, 38(6):872-890.e6

PubMed: 33217342 ( click the link to review the publication )
Clin Cancer Res, 2020, 10.1158

PubMed: 32034077 ( click the link to review the publication )

Cancer Cell, 2020, 37(3):387-402

PubMed: 32142667 ( click the link to review the publication )

Viruses, 2020, 12(10)E1128

PubMed: 33028008 ( click the link to review the publication )

Arch Virol, 2020, 10.1007/s00705-020-04524-7

PubMed: 31942645 ( click the link to review the publication )

Gastroenterology, 2019, 157(3):823-837

PubMed: 31078621 ( click the link to review the publication )

Gastroenterology, 2019, 156(3):577-581

PubMed: 30391471 ( click the link to review the publication )

Nat Cell Biol, 2019, 21(6):778-790

PubMed: 31160710 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2197

PubMed: 31097693 ( click the link to review the publication )

J Clin Invest, 2019, 10.1172/JCI128678

PubMed: 31805013 ( click the link to review the publication )

Nat Commun, 2019, 10(1-:2987

PubMed: 31278260 ( click the link to review the publication )

Nat Commun, 2019, 10(1):5549

PubMed: 31804471 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2919

PubMed: 31266962 ( click the link to review the publication )

Nat Commun, 2019, 10(1):5143

PubMed: 31723142 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432.CCR-18-4145

PubMed: 31285371 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432.CCR-19-1398

PubMed: 31492749 ( click the link to review the publication )

Dev Cell, 2019, 51(5):602-616.e12

PubMed: 31794718 ( click the link to review the publication )

Cancer Res, 2019, 79(10):2494-2510

PubMed: 30862719 ( click the link to review the publication )

Haematologica, 2019, 10.3324/haematol.2018.211110

PubMed: 30846494 ( click the link to review the publication )

Cell Rep, 2019, 29(3):573-588

PubMed: 31618628 ( click the link to review the publication )

Cell Rep, 2019, 27(3):806-819

PubMed: 30995478 ( click the link to review the publication )

Cell Rep, 2019, 29(1):118-134

PubMed: 31577942 ( click the link to review the publication )

Thyroid, 2019, 29(1):79-92

PubMed: 30398411 ( click the link to review the publication )

Redox Biol, 2019, 24:101189

PubMed: 30986607 ( click the link to review the publication )

Oncogene, 2019, 38(18):3402-3414

PubMed: 30643193 ( click the link to review the publication )
Oncogene, 2019, 101038/s41388-019-1136-4

PubMed: 31804622 ( click the link to review the publication )

EBioMedicine, 2019, 49:106-117

PubMed: 31668570 ( click the link to review the publication )

Stem Cell Reports, 2019,

PubMed: 31231022 ( click the link to review the publication )

Cancer Lett, 2019, 442:53-67

PubMed: 30391781 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):83

PubMed: 30770740 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 18;38(1):85

PubMed: 30777101 ( click the link to review the publication )

Cancers (Basel), 2019, 11(11)

PubMed: 31652979 ( click the link to review the publication )

PLoS Pathog, 2019,

PubMed: 30716130 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2019, 10.1111/pcmr.12812

PubMed: 31323160 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2019, 32(2):280-291

PubMed: 30277012 ( click the link to review the publication )

Cell Death Dis, 2019, 10(12):871

PubMed: 31740667 ( click the link to review the publication )

Br J Cancer, 2019, 121(9):758-767

PubMed: 31551581 ( click the link to review the publication )

Cells, 2019, 8(12)

PubMed: 31766464 ( click the link to review the publication )

Cells, 2019, 8(8)

PubMed: 31409052 ( click the link to review the publication )

PLoS Genet, 2019, 15(4):e1008077

PubMed: 30969964 ( click the link to review the publication )

Front Immunol, 2019, 10:2020

PubMed: 31507609 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(8):1439-1450

PubMed: 31142662 ( click the link to review the publication )

Mol Oncol, 2019, 13(2):290-306

PubMed: 30422399 ( click the link to review the publication )

Mol Oncol, 2019, 13(7):1467-1489

PubMed: 30919591 ( click the link to review the publication )

Cancer Sci, 2019, 110(8):2529-2539

PubMed: 31119819 ( click the link to review the publication )

Oncogenesis, 2019, 8(9):50

PubMed: 31492847 ( click the link to review the publication )

Transl Psychiatry, 2019, 9(1):306

PubMed: 31740729 ( click the link to review the publication )

Lab Invest, 2019, 10.1038/s41374-019-0274-1

PubMed: 31201369 ( click the link to review the publication )

Biochem Pharmacol, 2019, 169:113640

PubMed: 31536726 ( click the link to review the publication )
Sci Rep, 2019, 9(1):1897

PubMed: 30760778 ( click the link to review the publication )

Sci Rep, 2019, 9(1):13308

PubMed: 31527768 ( click the link to review the publication )

Sci Rep, 2019, 9(1):7779

PubMed: 31123282 ( click the link to review the publication )

Am J Physiol Lung Cell Mol Physiol, 2019, 316(1):L20-L34

PubMed: 30260287 ( click the link to review the publication )

Acta Pharmacol Sin, 2019, 10.1038/s41401-019-0268-y

PubMed: 31316177 ( click the link to review the publication )

Mol Pharmacol, 2019, 96(1):36-46

PubMed: 31048548 ( click the link to review the publication )

Mol Carcinog, 2019, 10.1002/mc.23123

PubMed: 31571292 ( click the link to review the publication )

Front Pharmacol, 2019, 10:1159

PubMed: 31649535 ( click the link to review the publication )

Int J Oncol, 2019, 54(3):1123-1133

PubMed: 30747223 ( click the link to review the publication )

Invest New Drugs, 2019, 10.1007/s10637-019-00795-3

PubMed: 31124056 ( click the link to review the publication )

Invest Ophthalmol Vis Sci, 2019, 60(1):349-357

PubMed: 30682205 ( click the link to review the publication )

Invest Ophthalmol Vis Sci, 2019, 60(7):2764-2772

PubMed: 31247083 ( click the link to review the publication )

Cell Cycle, 2019, 18(13):1513-1522

PubMed: 31135266 ( click the link to review the publication )

Cell Cycle, 2019, 18(5):596-604

PubMed: 30724698 ( click the link to review the publication )

J Mol Endocrinol, 2019, 63(3):199-213

PubMed: 31416049 ( click the link to review the publication )

Molecules, 2019, 24(3)

PubMed: 30754629 ( click the link to review the publication )

Transl Oncol, 2019, 12(8):1015-1025

PubMed: 31141756 ( click the link to review the publication )

Pathol Oncol Res, 2019, 25(2):769-775

PubMed: 30706361 ( click the link to review the publication )

Oncol Lett, 2019, 17(3):3569-3575

PubMed: 30867799 ( click the link to review the publication )

Anticancer Res, 2019, 39(7):3785-3793

PubMed: 31262905 ( click the link to review the publication )

Target Oncol, 2019, 14(5):619-626

PubMed: 31502118 ( click the link to review the publication )

Sci Adv, 2019, 5(8):eaav8463

PubMed: 31453322 ( click the link to review the publication )

JCI Insight, 2019, 4(4)

PubMed: 30830869 ( click the link to review the publication )

Br J Cancer, 2019, 10.1038/s41416-019-0673-5

PubMed: 31839677 ( click the link to review the publication )
Transl Oncol, 2019, 13(2):201-211

PubMed: 31865182 ( click the link to review the publication )

Oncotarget, 2019, 10(14):1440-1457

PubMed: 30858928 ( click the link to review the publication )

Oncotarget, 2019, 10(56):5755-5767

PubMed: 31645898 ( click the link to review the publication )

Heliyon, 2019, 6(1):e03031

PubMed: 31909243 ( click the link to review the publication )

Sci Transl Med, 2018, 10(450)

PubMed: 30021885 ( click the link to review the publication )

Cell Res, 2018, 28(7):719-729

PubMed: 29795445 ( click the link to review the publication )

Mol Cell, 2018, 70(5):949-960

PubMed: 29861159 ( click the link to review the publication )

Mol Psychiatry, 2018, 23(2):444-458

PubMed: 28070119 ( click the link to review the publication )

Nat Commun, 2018, 9(1):579

PubMed: 29422527 ( click the link to review the publication )

Nat Commun, 2018, 9(1):5416

PubMed: 30575746 ( click the link to review the publication )

Nat Commun, 2018, 9(1):2434

PubMed: 29934552 ( click the link to review the publication )

Nat Commun, 2018, 9(1):28

PubMed: 29295999 ( click the link to review the publication )

J Exp Med, 2018, 215(6):1693-1708

PubMed: 29769248 ( click the link to review the publication )

EMBO Mol Med, 2018, 10(9)

PubMed: 30108112 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(19):4854-4864

PubMed: 29945997 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(24):6367-6382

PubMed: 30135148 ( click the link to review the publication )

PLoS Biol, 2018,

PubMed: 30261040 ( click the link to review the publication )

Genome Med, 2018, 10(1):90

PubMed: 30482246 ( click the link to review the publication )

Biomaterials, 2018, 156:258-273

PubMed: 29222974 ( click the link to review the publication )

Theranostics, 2018, 8(5):1256-1269

PubMed: 29507618 ( click the link to review the publication )

Theranostics, 2018, 8(8):2134-2146

PubMed: 29721068 ( click the link to review the publication )

Cancer Res, 2018, 78(6):1444-1456

PubMed: 29321164 ( click the link to review the publication )

Int J Cancer, 2018, 142(2):381-391

PubMed: 28921565 ( click the link to review the publication )

Oncogene, 2018, 37(39):5340-5354

PubMed: 29858603 ( click the link to review the publication )
Cancer Lett, 2018, 414:268-277

PubMed: 29179997 ( click the link to review the publication )

Cancers (Basel), 2018, 10(11)

PubMed: 30373214 ( click the link to review the publication )

Breast Cancer Res, 2018, 20(1):9

PubMed: 29382358 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2018, 31(2):253-266

PubMed: 28972303 ( click the link to review the publication )

Cell Death Dis, 2018, 9(11):1052

PubMed: 30323190 ( click the link to review the publication )

Cell Death Dis, 2018, 9(2):123

PubMed: 29374144 ( click the link to review the publication )

Br J Cancer, 2018, 119(6):713-723

PubMed: 30116025 ( click the link to review the publication )

J Clin Med, 2018, 7(5)

PubMed: 29762469 ( click the link to review the publication )

Cancer Discov, 2018, 8(10):1237-1249

PubMed: 30045908 ( click the link to review the publication )

Cell Physiol Biochem, 2018, 49(4):1499-1511

PubMed: 30205377 ( click the link to review the publication )

Bioinformatics, 2018, 34(17):i997-i1004

PubMed: 30423075 ( click the link to review the publication )

Bioinformatics, 2018, 34(23):4079-4086

PubMed: 29931053 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(11-:2329-2340

PubMed: 30166401 ( click the link to review the publication )

Br J Haematol, 2018, 182(6):921-924

PubMed: 28771685 ( click the link to review the publication )

Cancer Sci, 2018, 109(12):3816-3825

PubMed: 30343534 ( click the link to review the publication )

Oncogenesis, 2018, 7(9):67

PubMed: 30190455 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(11):1773-1784

PubMed: 29967110 ( click the link to review the publication )

Int J Mol Sci, 2018, 19(7)

PubMed: 30018229 ( click the link to review the publication )

Sci Rep, 2018, 8(1):850

PubMed: 29339801 ( click the link to review the publication )

Sci Rep, 2018,

PubMed: 29849102 ( click the link to review the publication )

J Biol Chem, 2018, 293(23):9113-9123

PubMed: 29540478 ( click the link to review the publication )

Front Pharmacol, 2018, 8:988

PubMed: 29379440 ( click the link to review the publication )

Mol Cell Endocrinol, 2018, 474:20-34

PubMed: 29428395 ( click the link to review the publication )

Cell Signal, 2018, 44:127-137

PubMed: 29329780 ( click the link to review the publication )
Cell Signal, 2018, 42:11-20

PubMed: 28986121 ( click the link to review the publication )

Am J Physiol, Cell Physiol, 2018,

PubMed: 30257106 ( click the link to review the publication )

Cell Cycle, 2018, 17(4):428-438

PubMed: 29468929 ( click the link to review the publication )

PLoS One, 2018, 13(2):e0191890

PubMed: 29389967 ( click the link to review the publication )

Med Sci Monit, 2018, 24:8048-8055

PubMed: 30414267 ( click the link to review the publication )

Med Sci Monit, 2018, 24:3002-3010

PubMed: 29737325 ( click the link to review the publication )

Exp Lung Res, 2018, 44(7):332-343

PubMed: 30676129 ( click the link to review the publication )

Oncol Lett, 2018, 16(1):326-334

PubMed: 29928418 ( click the link to review the publication )

Oncotarget, 2018, 9(100):37352-37366

PubMed: 30647837 ( click the link to review the publication )

Nat Methods, 2018, 15(9):732-740

PubMed: 30127506 ( click the link to review the publication )

Cell Death Dis, 2018, 9(2):31

PubMed: 29348467 ( click the link to review the publication )

BMC Cancer, 2018, 18(1):542

PubMed: 29739364 ( click the link to review the publication )

Cancer Discov, 2018, 8(11):1458-1473

PubMed: 30185628 ( click the link to review the publication )

Oncotarget, 2018, 9(74):33995-34008

PubMed: 30338041 ( click the link to review the publication )

Gut, 2017, 66(6):1106-1115

PubMed: 27670374 ( click the link to review the publication )

J Clin Invest, 2017, 127(6):2081-2090

PubMed: 28504649 ( click the link to review the publication )

Nat Commun, 2017, 8;8:15617

PubMed: 28593995 ( click the link to review the publication )

Nat Commun, 2017, 8(1):1090

PubMed: 29061961 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(21):6567-6579

PubMed: 28765329 ( click the link to review the publication )

Neuro Oncol, 2017, 20(6):764-775

PubMed: 29136244 ( click the link to review the publication )

J Cell Biol, 2017, 216(6):1567-1577

PubMed: 28442534 ( click the link to review the publication )

Int J Cancer, 2017, 140(12):2758-2770

PubMed: 27813079 ( click the link to review the publication )

Cancer Lett, 2017, 408:130-137

PubMed: 28866094 ( click the link to review the publication )

Br J Cancer, 2017, 116(8):1065-1076

PubMed: 28301874 ( click the link to review the publication )
Cancer Discov, 2017, 7(4):369-379

PubMed: 28122867 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(10):2234-2245

PubMed: 28729401 ( click the link to review the publication )

Sci Rep, 2017, 7:44123

PubMed: 28276530 ( click the link to review the publication )

J Steroid Biochem Mol Biol, 2017, 165(Pt B):258-267

PubMed: 27369115 ( click the link to review the publication )

J Biol Chem, 2017, 292(10):3970-3976

PubMed: 28179426 ( click the link to review the publication )

Urol Oncol, 2017, 35(1):32

PubMed: 27692847 ( click the link to review the publication )

Front Physiol, 2017, 7:682

PubMed: 28149280 ( click the link to review the publication )

Int J Biochem Cell Biol, 2017, 85:149-158

PubMed: 28254430 ( click the link to review the publication )

Melanoma Res, 2017, 27(6):545-557

PubMed: 29076949 ( click the link to review the publication )

PLoS One, 2017, 12(9):e0184861

PubMed: 28910386 ( click the link to review the publication )

PLoS One, 2017, 12(1):e0170445

PubMed: 28118392 ( click the link to review the publication )

Am J Reprod Immunol, 2017, 78(4)

PubMed: 28635072 ( click the link to review the publication )

ACS Omega, 2017, 2(11):7868-7880

PubMed: 30023564 ( click the link to review the publication )

Medchemcomm, 2017, 8(1):88-95

PubMed: 28670440 ( click the link to review the publication )

SLAS Discov, 2017, 22(5):507-515

PubMed: 28324660 ( click the link to review the publication )

Anticancer Res, 2017, 37(2):607-614

PubMed: 28179307 ( click the link to review the publication )

Biotechnol Lett, 2017, 39(7):1069-1077

PubMed: 28353145 ( click the link to review the publication )

Oncotarget, 2017, 8(8):13174-13185

PubMed: 28061458 ( click the link to review the publication )

JCI Insight, 2017, 2(3):e89473

PubMed: 28194436 ( click the link to review the publication )

Oncotarget, 2017, 8(61):104193-104205

PubMed: 29262632 ( click the link to review the publication )

Oncotarget, 2017, 8(52):90037-90049

PubMed: 29163809 ( click the link to review the publication )

Oncotarget, 2017, 8(19):31666-31681

PubMed: 28427224 ( click the link to review the publication )

Oncotarget, 2017, 8(22):36628-36638

PubMed: 28410230 ( click the link to review the publication )

Oncotarget, 2017, 8(55):94606-94618

PubMed: 29212253 ( click the link to review the publication )
Oncotarget, 2017, 8(18):30151-30161

PubMed: 28404914 ( click the link to review the publication )

Oncotarget, 2017, 9(5):5529-5544

PubMed: 29464016 ( click the link to review the publication )

Oncotarget, 2017,

PubMed: 28938614 ( click the link to review the publication )

Oncotarget, 2017, 8(8):13174-13185

PubMed: 28061458 ( click the link to review the publication )

Oncotarget, 2017,

PubMed: 29113345 ( click the link to review the publication )

Oncotarget, 2017, 8(52):90037-90049

PubMed: 29163809 ( click the link to review the publication )

Oncotarget, 2017, 8(7):11460-11479

PubMed: 28002790 ( click the link to review the publication )

Elife, 2017, 6

PubMed: 28350298 ( click the link to review the publication )

Cell, 2017, 168(5):890-903

PubMed: 28162770 ( click the link to review the publication )

J Exp Med, 2017, 214(6):1691-1710

PubMed: 28450382 ( click the link to review the publication )

Oncotarget, 2017, 8(49):84697-84713

PubMed: 29156677 ( click the link to review the publication )

Medchemcomm, 2017, 8(1):88-95

PubMed: 28670440 ( click the link to review the publication )

Melanoma Res, 2017, 27(6):545-557

PubMed: 29076949 ( click the link to review the publication )

JCI Insight, 2017, 2(3):e89473

PubMed: 28194436 ( click the link to review the publication )

Oncotarget, 2017, 9(3):3815-3829

PubMed: 29423085 ( click the link to review the publication )

Oncotarget, 2017, 8(22):36628-36638

PubMed: 28410230 ( click the link to review the publication )

Oncotarget, 2017, 8(18):30151-30161

PubMed: 28404914 ( click the link to review the publication )

Oncotarget, 2017, 8(19):31666-31681

PubMed: 28427224 ( click the link to review the publication )

Hepatology, 2016, 64(2):488-500

PubMed: 27015352 ( click the link to review the publication )

Genome Biol, 2016, 17:80

PubMed: 27139883 ( click the link to review the publication )

Nat Commun, 2016, 7:11363

PubMed: 27193833 ( click the link to review the publication )

J Clin Invest, 2016, 126(1):349-64

PubMed: 26657862 ( click the link to review the publication )

Nat Commun, 2016, 7:13615

PubMed: 27897178 ( click the link to review the publication )

Clin Cancer Res, 2016, 10.1158/1078-0432.CCR-15-2987

PubMed: 27185371 ( click the link to review the publication )
Clin Cancer Res, 2016, 22(21):5370-5382

PubMed: 27178741 ( click the link to review the publication )

Clin Cancer Res, 2016, 22(24):6021-6030

PubMed: 27259561 ( click the link to review the publication )

Leukemia, 2016, 30(9):1832-43

PubMed: 27174491 ( click the link to review the publication )

Cancer Res, 2016, 76(3):675-85

PubMed: 26676756 ( click the link to review the publication )

Cancer Res, 2016, 76(20):6095-6106

PubMed: 27569217 ( click the link to review the publication )

Elife, 2016, 10.7554/eLife.11414

PubMed: 26999821 ( click the link to review the publication )

Elife, 2016, 10.7554/eLife.18489

PubMed: 27845624 ( click the link to review the publication )

J Invest Dermatol, 2016, 136(12):2475-2484

PubMed: 27498344 ( click the link to review the publication )

Cancers (Basel), 2016,

PubMed: 27187477 ( click the link to review the publication )

Cell Death Dis, 2016, 7(10):e2432

PubMed: 27787516 ( click the link to review the publication )

Cell Chem Biol, 2016, 23(12):1550-1559

PubMed: 27939899 ( click the link to review the publication )

Mol Cancer Ther, 2016, 15(7):1460-71

PubMed: 27196754 ( click the link to review the publication )

Mol Oncol, 2016, 10(1):101-12

PubMed: 26471831 ( click the link to review the publication )

Mol Cell Proteomics, 2016, 15(3):1139-50

PubMed: 26933192 ( click the link to review the publication )

Mol Cancer Res, 2016, 14(12):1204-1216

PubMed: 27655129 ( click the link to review the publication )

Mol Pharm, 2016, 13(11):3724-3735

PubMed: 27653969 ( click the link to review the publication )

Mol Cancer Res, 2016,

PubMed: 26582713 ( click the link to review the publication )

Sci Rep, 2016, 6:26803

PubMed: 27222248 ( click the link to review the publication )

Sci Rep, 2016,

PubMed: 27412232 ( click the link to review the publication )

J Biol Chem, 2016, 291(41):21694-21702

PubMed: 27576686 ( click the link to review the publication )

BMC Genomics, 2016, 17(1):723

PubMed: 27613601 ( click the link to review the publication )

Int J Oncol, 2016, 49(3):953-60

PubMed: 27572939 ( click the link to review the publication )

Biochemistry, 2016, 10.1172/JCI81468

PubMed: 26974155 ( click the link to review the publication )

PLoS One, 2016, 11(1):e0147682

PubMed: 26821351 ( click the link to review the publication )
PLoS One, 2016, 11(9):e0162634

PubMed: 27611696 ( click the link to review the publication )

PLoS One, 2016, 11(5):e0155893

PubMed: 27196001 ( click the link to review the publication )

Thorac Cancer, 2016, 7(3):279-87

PubMed: 27148412 ( click the link to review the publication )

PeerJ, 2016, 4:e1683

PubMed: 26893968 ( click the link to review the publication )

Leuk Res, 2016, 50:1-10

PubMed: 27626202 ( click the link to review the publication )

Methods Enzymol, 2016, 568:557-80

PubMed: 26795484 ( click the link to review the publication )

Oncotarget, 2016,

PubMed: 26936993 ( click the link to review the publication )

Oncotarget, 2016, 7(2):1598-607

PubMed: 26624982 ( click the link to review the publication )

Oncotarget, 2016, 7(8):9102-17

PubMed: 26802022 ( click the link to review the publication )

Oncotarget, 2016, 7(50):83424-83436

PubMed: 27825137 ( click the link to review the publication )

Oncotarget, 2016, 7(40):65147-65156

PubMed: 27556501 ( click the link to review the publication )

Integr Biol, 2016, 8(1):73-90

PubMed: 26658688 ( click the link to review the publication )

Oncotarget, 2016, 7(7):7960-9

PubMed: 26799289 ( click the link to review the publication )

Oncotarget, 2016, 7(31):49597-49610

PubMed: 27391062 ( click the link to review the publication )

Oncotarget, 2016, 7(15):19575-88

PubMed: 26988909 ( click the link to review the publication )

Mol Cancer Ther, 2016, 15(1):172-83

PubMed: 26487278 ( click the link to review the publication )

Elife, 2016, 5

PubMed: 27557444 ( click the link to review the publication )

Oncotarget, 2016, 7(8):9102-17

PubMed: 26802022 ( click the link to review the publication )

Oncotarget, 2016, 7(21):30907-23

PubMed: 27127178 ( click the link to review the publication )

Oncotarget, 2016,

PubMed: 27150057 ( click the link to review the publication )

Oncotarget, 2016, 7(40):65147-65156

PubMed: 27556501 ( click the link to review the publication )

Oncotarget, 2016, 7(12):13797-809

PubMed: 26883194 ( click the link to review the publication )

Oncotarget, 2016, 7(4):3947-65

PubMed: 26678033 ( click the link to review the publication )

Oncotarget, 2016, 7(48):78396-78411

PubMed: 27623078 ( click the link to review the publication )
Oncotarget, 2016, 7(50):83424-83436

PubMed: 27825137 ( click the link to review the publication )

Oncotarget, 2016,

PubMed: 27174919 ( click the link to review the publication )

Cell Res, 2015, 10.1038/cr.2015.30

PubMed: 25753158 ( click the link to review the publication )

Nat Commun, 2015, 6:8583

PubMed: 26456302 ( click the link to review the publication )

Nat Commun, 2015, 6:7769

PubMed: 26183061 ( click the link to review the publication )

J Natl Cancer Inst, 2015, 108(6):djv406

PubMed: 26719346 ( click the link to review the publication )

Clin Cancer Res, 2015, 10.1158/1078-0432.CCR-15-0013

PubMed: 26034127 ( click the link to review the publication )

Leukemia, 2015, 29(3):705-14

PubMed: 25102946 ( click the link to review the publication )

Leukemia, 2015, 29(4):828-38

PubMed: 25322685 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2015, 112(32):9990-5

PubMed: 26216950 ( click the link to review the publication )

Neuro Oncol, 2015, 10.1093/neuonc/nou369

PubMed: 25712957 ( click the link to review the publication )

Cancer Res, 2015, 10.1158/0008-5472.CAN-15-0370

PubMed: 25952648 ( click the link to review the publication )

Cancer Res, 2015, 75(5):880-91

PubMed: 25432174 ( click the link to review the publication )

Elife, 2015,

PubMed: 25686219 ( click the link to review the publication )

Oncogene, 2015, 10.1038/onc.2015.97

PubMed: 25867065 ( click the link to review the publication )

Oncogene, 2015, 10.1038/onc.2015.12

PubMed: 25684139 ( click the link to review the publication )

Cancer Lett, 2015, 364(1):70-8

PubMed: 25937299 ( click the link to review the publication )

J Invest Dermatol, 2015, 135(7):1863-1872

PubMed: 25789707 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2015, 28(5):572-89

PubMed: 26112748 ( click the link to review the publication )

J Neurosci, 2015, 35(3):972-84

PubMed: 25609615 ( click the link to review the publication )

J Neurosci, 2015, 35(7):3034-47

PubMed: 25698741 ( click the link to review the publication )

FASEB J, 2015, 10.1096/fj.14-267278

PubMed: 25857555 ( click the link to review the publication )

Mol Cancer Ther, 2015, 14(12):2831-9

PubMed: 26438159 ( click the link to review the publication )

Mol Cancer Ther, 2015, 10.1158/1535-7163.MCT-14-0810

PubMed: 25777962 ( click the link to review the publication )
Mol Oncol, 2015, 9(7):1434-46

PubMed: 25933688 ( click the link to review the publication )

Mol Cell Proteomics, 2015, 10.1074/mcp.M115.049783 mcp.M115.049783.

PubMed: 25953087 ( click the link to review the publication )

J Cancer, 2015, 6(12):1195-205

PubMed: 26535060 ( click the link to review the publication )

Gynecol Oncol, 2015, 139(1):118-26

PubMed: 26232337 ( click the link to review the publication )

Gynecol Oncol, 2015, 138(1):165-73

PubMed: 25933683 ( click the link to review the publication )

Front Oncol, 2015, 5:135

PubMed: 26137449 ( click the link to review the publication )

Antimicrob Agents Chemother, 2015, 59(2):1088-99

PubMed: 25487801 ( click the link to review the publication )

J Transl Med, 2015, 13:210

PubMed: 26139106 ( click the link to review the publication )

Eur Neuropsychopharm, 2015, 10.1016/j.euroneuro.2014.12.007

PubMed: 25624003 ( click the link to review the publication )

Am J Physiol Endocrinol Metab, 2015, 308(10):E899-911

PubMed: 25805192 ( click the link to review the publication )

J Biol Chem, 2015, 290(28):17495-504

PubMed: 26023239 ( click the link to review the publication )

Biochem J, 2015, 465(2):227-38

PubMed: 25353634 ( click the link to review the publication )

Respir Res, 2015, 16:48

PubMed: 25890309 ( click the link to review the publication )

Int J Oncol, 2015, 47(3):849-56

PubMed: 26179332 ( click the link to review the publication )

Cell Signal, 2015, 27(11):2191-200

PubMed: 26210887 ( click the link to review the publication )

Cell Signal, 2015, 27(10):1939-48

PubMed: 26163823 ( click the link to review the publication )

Prostate, 2015, 10.1002/pros.22945

PubMed: 25560638 ( click the link to review the publication )

Exp Cell Res, 2015, 332(1):1-10

PubMed: 25637219 ( click the link to review the publication )

BMC Cancer, 2015, 15:894

PubMed: 26560145 ( click the link to review the publication )

Radiat Oncol, 2015, 10:214

PubMed: 26498922 ( click the link to review the publication )

PLoS One, 2015, 10(9):e0137917

PubMed: 26360058 ( click the link to review the publication )

PLoS One, 2015, 10(12):e0143847

PubMed: 26630652 ( click the link to review the publication )

Biochem Biophys Res Commun, 2015, 456(3):821-6

PubMed: 25498501 ( click the link to review the publication )

J Biotechnol, 2015, 10.1016/j.jbiotec.2015.01.012

PubMed: 25615947 ( click the link to review the publication )
Oncotarget, 2015,

PubMed: 26036637 ( click the link to review the publication )

Oncotarget, 2015, 6(5):3165-77

PubMed: 25638158 ( click the link to review the publication )

Oncotarget, 2015, 6(32):33623-35

PubMed: 26378038 ( click the link to review the publication )

Oncotarget, 2015, 6(19):17491-500

PubMed: 26036637 ( click the link to review the publication )

Oncotarget, 2015,

PubMed: 26325669 ( click the link to review the publication )

Oncotarget, 2015, 6(16):14472-87

PubMed: 25961376 ( click the link to review the publication )

Oncotarget, 2015, 6(32):33397-409

PubMed: 26397223 ( click the link to review the publication )

Oncotarget, 2015,

PubMed: 26544513 ( click the link to review the publication )

Oncotarget, 2015, 6(32):33623-35

PubMed: 26378038 ( click the link to review the publication )

Cell, 2015, 162(6):1271-85

PubMed: 26359985 ( click the link to review the publication )

EMBO Mol Med, 2015, 7(9):1104-18

PubMed: 26105199 ( click the link to review the publication )

Oncotarget, 2015, 6(31):31792-804

PubMed: 26397139 ( click the link to review the publication )

Oncotarget, 2015, 6(11):8698-708

PubMed: 25826088 ( click the link to review the publication )

Oncotarget, 2015,

PubMed: 26317790 ( click the link to review the publication )

J Invest Dermatol, 2015, 135(7):1863-1872

PubMed: 25789707 ( click the link to review the publication )

Cell Signal, 2015, 27(11):2191-200

PubMed: 26210887 ( click the link to review the publication )

Mol Cancer Ther, 2015, 14(12):2700-11

PubMed: 26351322 ( click the link to review the publication )

Nano Lett, 2015, 15(12):8032-43

PubMed: 26540670 ( click the link to review the publication )

Blood, 2014, 27;124(23):3420-30

PubMed: 25253770 ( click the link to review the publication )

Nat Commun, 2014, 5:3901

PubMed: 24849047 ( click the link to review the publication )

Nucleic Acids Res, 2014, 42(8):5083-96

PubMed: 24526220 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(23):6023-33

PubMed: 25316819 ( click the link to review the publication )

Leukemia, 2014, 10.1038/leu.2014.187.

PubMed: 24912431 ( click the link to review the publication )

Cancer Res, 2014, 74(10):2825-34

PubMed: 24648348 ( click the link to review the publication )
Cancer Res, 2014, 74(20):5866-77

PubMed: 25168481 ( click the link to review the publication )

Oncogene, 2014, 33(33):4236-41

PubMed: 24469055 ( click the link to review the publication )

Oncogene, 2014, 10.1038/onc.2014.392

PubMed: 25435367 ( click the link to review the publication )

J Invest Dermatol, 2014, 134(2):366-73

PubMed: 23924903 ( click the link to review the publication )

Sci Signal, 2014, 7(311):ra12

PubMed: 24497609 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2014, 27(3):479-84

PubMed: 24422853 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2014, 27(6):1154-8

PubMed: 25130256 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1434

PubMed: 25275595 ( click the link to review the publication )

FASEB J, 2014, 10.1096/fj.13-247924

PubMed: 24903273 ( click the link to review the publication )

Mol Cancer Ther, 2014, 13(2):353-63

PubMed: 24398428 ( click the link to review the publication )

Mol Cancer Ther, 2014, 13(7):1894-906

PubMed: 24825855 ( click the link to review the publication )

Mol Cancer Ther, 2014, 10.1158/1535-7163.MCT-14-0452

PubMed: 25349308 ( click the link to review the publication )

Endocr Relat Cancer, 2014, 21(2):161-73

PubMed: 24243688 ( click the link to review the publication )

Mol Nutr Food Res, 2014, 58(3):528-36

PubMed: 24039193 ( click the link to review the publication )

Gastric Cancer, 2014, 10.1007/s10120-014-0444-1

PubMed: 25407459 ( click the link to review the publication )

Hum Mol Genet, 2014, 23(1):1-11

PubMed: 23933734 ( click the link to review the publication )

Mol Cancer Res, 2014, 12(10):1509-19

PubMed: 24962318 ( click the link to review the publication )

Mol Cell Biol, 2014, 34(22):4088-103

PubMed: 25182533 ( click the link to review the publication )

Neuroscience, 2014, 562:69-74

PubMed: 24412130 ( click the link to review the publication )

Virology, 2014, 468-470C:490-503

PubMed: 25261871 ( click the link to review the publication )

Cancer Biol Ther, 2014, 15(9):1239-47

PubMed: 24971884 ( click the link to review the publication )

Exp Cell Res, 2014, 327(2):340-52

PubMed: 25128814 ( click the link to review the publication )

Cell Cycle, 2014, 13(24):3808-17

PubMed: 25426675 ( click the link to review the publication )

Cell Cycle, 2014, 13(24):3808-17

PubMed: ( click the link to review the publication )
BMC Cancer, 2014, 14(1):240

PubMed: 24708867 ( click the link to review the publication )

Cancer Chemother Pharmacol, 2014, 73(2):259-70

PubMed: 24253175 ( click the link to review the publication )

PLoS One, 2014, 9(2):e83957

PubMed: 24551032 ( click the link to review the publication )

PLoS One, 2014, 9(12):e115068

PubMed: 25500581 ( click the link to review the publication )

PLoS One, 2014, 9(10):e110306

PubMed: 25330306 ( click the link to review the publication )

PLoS One, 2014, 9(5):e97938

PubMed: 24835245 ( click the link to review the publication )

PLoS One, 2014, 9(2):e89646

PubMed: 24586933 ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 452(4):958-61

PubMed: 25218145 ( click the link to review the publication )

Radiat Res, 2014, 182(3):350-62

PubMed: 25117621 ( click the link to review the publication )

Sensors (Basel), 2014, 14(3):5074-117

PubMed: 24625737 ( click the link to review the publication )

The University of Texas, 2014, Lizee S

PubMed: ( click the link to review the publication )

Oncotarget, 2014,

PubMed: 24962990 ( click the link to review the publication )

Mol Cancer, 2014, 13:154

PubMed: 24941944 ( click the link to review the publication )

Tumor Biol, 2014, 35(10):9759-67

PubMed: 24972969 ( click the link to review the publication )

Assay Drug Dev Technol, 2014, 12(9-10):514-26

PubMed: 25506801 ( click the link to review the publication )

Oncotarget, 2014, 5(21):10732-44

PubMed: 25313141 ( click the link to review the publication )

Blood, 2013, 121(23):4617-26

PubMed: 23575444 ( click the link to review the publication )

Blood, 2013, 121(19):3879-88, S1-8

PubMed: 23460614 ( click the link to review the publication )

Hepatology, 2013, 59(4):1435-47

PubMed: 24242874 ( click the link to review the publication )

J Clin Invest, 2013, 124(1):156-68

PubMed: 24316974 ( click the link to review the publication )

J Clin Invest, 2013, 123(6):2551-63

PubMed: 23635776 ( click the link to review the publication )

J Clin Invest, 2013, 123(5):2155-68

PubMed: 23543055 ( click the link to review the publication )

J Natl Cancer Inst, 2013, 105(1):33-46

PubMed: 23250956 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(20):5749-57

PubMed: 23948972 ( click the link to review the publication )
Clin Cancer Res, 2013, 19(9):2584-91

PubMed: 23515407 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(1):118-27

PubMed: 23091117 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2013, 10.1038/onc.2013.389

PubMed: 24096476 ( click the link to review the publication )

Cancer Res, 2013, 73(23):7101-10

PubMed: 24121492 ( click the link to review the publication )

Cancer Res, 2013, 73(20):6346-58

PubMed: 23966295 ( click the link to review the publication )

Mol Syst Biol, 2013,

PubMed: 23752269 ( click the link to review the publication )

Cell Rep, 2013, 4(6):1090-9

PubMed: 24055054 ( click the link to review the publication )

Oncogene, 2013, 33(33):4236-41

PubMed: 24336323 ( click the link to review the publication )

Sci Signal, 2013, 6(271):ra25

PubMed: 23592840 ( click the link to review the publication )

Sci Signal, 2013, 5(206):ra3

PubMed: 22234612 ( click the link to review the publication )

Sci Signal, 2013,

PubMed: 23532334 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2013, 26(4):518-26

PubMed: 23582185 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2013, 26(4):509-17

PubMed: 23490205 ( click the link to review the publication )

J Neurosci, 2013, 33(10):4280-94

PubMed: 23467345 ( click the link to review the publication )

Exp Mol Med, 2013, 45:e64

PubMed: 24263233 ( click the link to review the publication )

Cancer Discov, 2013, 3(4):444-57

PubMed: 23358651 ( click the link to review the publication )

Mol Cancer Ther, 2013, 12(6):1131-9

PubMed: 23515613 ( click the link to review the publication )

J Mol Cell Cardiol, 2013, 59:139-47

PubMed: 23510923 ( click the link to review the publication )

Carcinogenesis, 2013, 34(3):638-46

PubMed: 23172668 ( click the link to review the publication )

Cancer Sci, 2013, 104(7):896-903

PubMed: 23578175 ( click the link to review the publication )

Skelet Muscle, 2013, 3(1):17

PubMed: 23815988 ( click the link to review the publication )

Exp Cell Res, 2013, 319(12):1732-43

PubMed: 23701950 ( click the link to review the publication )

Cell Cycle, 2013, 12(13):2073-83

PubMed: 23759592 ( click the link to review the publication )

Oncol Rep, 2013, 29(2):812-8

PubMed: 23229346 ( click the link to review the publication )
PLoS One, 2013, 8(10):e77243

PubMed: 24130864 ( click the link to review the publication )

PLoS One, 2013, 500(7461):222-6

PubMed: 24349570 ( click the link to review the publication )

PLoS One, 2013, 8(7):e68817

PubMed: 23935891 ( click the link to review the publication )

J Surg Res, 2013, 184(2):898-906

PubMed: 23602735 ( click the link to review the publication )

Oncotarget, 2013, 4(9):1496-506

PubMed: 24036604 ( click the link to review the publication )

University of Southampton, 2013, University of Southampton

PubMed: ( click the link to review the publication )

Nature, 2013, 504(7478):138-42

PubMed: 24185007 ( click the link to review the publication )

Cancer Res, 2013, 73(15):4840-51

PubMed: 23737487 ( click the link to review the publication )

Gut, 2012, 61(2):202-13

PubMed: 21813469 ( click the link to review the publication )

J Clin Invest, 2012, 122(7):2637-51

PubMed: 22653055 ( click the link to review the publication )

J Thorac Oncol, 2012, 7(2):272-80

PubMed: 22089117 ( click the link to review the publication )

Cell Death Differ, 2012, 19(12):2029-39

PubMed: 22858545 ( click the link to review the publication )

Oncogene, 2012, 31(27):3277-86

PubMed: 22020336 ( click the link to review the publication )

Cancer Lett, 2012, 316(1):77-84

PubMed: 22082529 ( click the link to review the publication )

Sci Signal, 2012, 5(224):rs4

PubMed: 22589389 ( click the link to review the publication )

Cardiovasc Res, 2012, 93(2):311-9

PubMed: 22068161 ( click the link to review the publication )

Mol Cancer Ther, 2012, 11(2):317-28

PubMed: 22188813 ( click the link to review the publication )

Endocr Relat Cancer, 2012, 19(1):29-38

PubMed: 22109971 ( click the link to review the publication )

Carcinogenesis, 2012, 33(5):956-61

PubMed: 22327936 ( click the link to review the publication )

Am J Pathol, 2012, 180(6):2462-78

PubMed: 22546478 ( click the link to review the publication )

J Biol Chem, 2012, 287(50):41797-807

PubMed: 23076151 ( click the link to review the publication )

Surgery, 2012, 152(6):1142-9

PubMed: 23158184 ( click the link to review the publication )

Am J Physiol Cell Physiol, 2012, 304(5):C431-9

PubMed: 23255578 ( click the link to review the publication )

Neuroscience, 2012, 206:224-36

PubMed: 22280975 ( click the link to review the publication )
Cancer Biol Ther, 2012, 13(1):43-9

PubMed: 22336587 ( click the link to review the publication )

PLoS One, 2012, 7(9):e42441

PubMed: 22957020 ( click the link to review the publication )

PLoS One, 2012, 7(8):e44146

PubMed: 22952903 ( click the link to review the publication )

PLoS One, 2012, 7(1):e29622

PubMed: 22253748 ( click the link to review the publication )

J Biomol Screen, 2012, 17(6):813-21

PubMed: 22453235 ( click the link to review the publication )

Aging, 2012, 4(11):803-822

PubMed: 23362510 ( click the link to review the publication )

Cancer Res, 2011, 71(15):5067-74

PubMed: 21803746 ( click the link to review the publication )

Biomaterials, 2011, 32(35):9197-206

PubMed: 21899882 ( click the link to review the publication )

Mol Syst Biol, 2011, 7:489

PubMed: 21613978 ( click the link to review the publication )

J Invest Dermatol, 2011, 132(2):356-64

PubMed: 21993556 ( click the link to review the publication )

J Clin Endocrinol Metab, 2011, 97(2):E173-82

PubMed: 22090271 ( click the link to review the publication )

Mol Cancer Res, 2011, 9(5):545-52

PubMed: 21478267 ( click the link to review the publication )

Endocrinology, 2011, 152(7):2589-98

PubMed: 21521747 ( click the link to review the publication )

Mol Endocrinol, 2011, 25(12):2041-53

PubMed: 22053001 ( click the link to review the publication )

Cancer Biol Ther, 2011, 12(3):215-28

PubMed: 21642769 ( click the link to review the publication )

Biol Reprod, 2011, 85(1):42-50

PubMed: 21349822 ( click the link to review the publication )

PLoS One, 2011, 6(12):e28973

PubMed: 22194965 ( click the link to review the publication )

Cancer Res, 2010, 70(11):4709-18

PubMed: 20484037 ( click the link to review the publication )

Brit J Haematol, 2010, 149(4):537-49

PubMed: 20331454 ( click the link to review the publication )

Methods Mol Biol, 2010, 661:107-22

PubMed: 20811979 ( click the link to review the publication )

Nature, 2010, 468(7326):973-7

PubMed: 21107323 ( click the link to review the publication )

P Natl Acad Sci USA, 2009, 106(48):20411-6

PubMed: 19915144 ( click the link to review the publication )

产品安全说明书

MEK抑制剂选择性比较

生物活性

产品描述

特性

AZD6244是第一个处于随机二期研究的MEK抑制剂。

靶点

MEK1 ^[1] (Cell-free assay)	MEK1 ^[13] (Cell-free assay)	MEK2 ^[13] (Cell-free assay)
14 nM	99 nM(Kd)	530 nM(Kd)

体外研究

AZD6244是ATP非竞争性的抑制剂，在IC50浓度小于40 nM时使ERK1/2的磷酸化作用失活。AZD6244也通过抑制ERK1/2和p90RSK的磷酸化抑制原代HCC细胞的生长，同时伴随着caspase-3和caspase-7分裂的加强, 及断裂的聚腺苷二磷酸核糖聚合酶的增多。AZD6244在P38，JNK，PI3K，及MEK5/ERK5通路中的作用不大。^[1]AZD6244对感知乳腺癌细胞系中的raf突变和非小细胞肺癌细胞系中的ras突变很灵敏。^[2]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
CHP-212	NF\XUGpIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	NXqwXZVsUW6qaXLpeIlwdiCxZjDoeY1idiCFSGCtNlEzKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSByLkCwN\|E2OyEQvF2u	NF\meGE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
H9	NH7XTm9Iem:5dHigbY5pcWKrdHnvckBie3OjeR?=	NH3EVoFKdmirYnn0bY9vKG:oIHj1cYFvKEh7IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTCwMlAzOjh6IN88UU4>	M4XZZ\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
HL-60	NF22bXFIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	NE\x[5hKdmirYnn0bY9vKG:oIHj1cYFvKEiOLU[wJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAxNjB{NEW5JO69VS5?	MoPqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
NOMO-1	NXnTRnBtT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	MUXJcohq[mm2aX;uJI9nKGi3bXHuJG5QVU9vMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gNE4xOzF7NzFOwG0v	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
DU-4475	MXnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	MoWwTY5pcWKrdHnvckBw\iCqdX3hckBFXS12NEe1JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAxNjB\|M{[3JO69VS5?	M2LCNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
M14	M1i0Rmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	MWTJcohq[mm2aX;uJI9nKGi3bXHuJG0yPCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxKD1iMD6wN\|Y5QSEQvF2u	M1vGd\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
HT-144	NIH5O5dIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	NUL0flM3UW6qaXLpeIlwdiCxZjDoeY1idiCKVD2xOFQh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDBwMEi5NFUh\|ryPLh?=	M3S1ZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
SK-N-AS	NFPXeJlIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	M2XXfWlvcGmkaYTpc44hd2ZiaIXtZY4hW0tvTj3BV{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOC5yOUK4N{DPxE1w	NX;vWnVNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
LB2518-MEL	MnfVS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	MYHJcohq[mm2aX;uJI9nKGi3bXHuJGxDOjVzOD3NSWwh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDBwMEmzPFIh\|ryPLh?=	Ml7UQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
C32	NULubWkzT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	M4nMOGlvcGmkaYTpc44hd2ZiaIXtZY4hSzN{IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTCwMlA6QDJ\|IN88UU4>	NVW0W29ORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
BHT-101	MVPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	NFvOcGJKdmirYnn0bY9vKG:oIHj1cYFvKEKKVD2xNFEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDBwMUC2PVMh\|ryPLh?=	MlLQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
KY821	Mk\tS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	NYHXfHpDUW6qaXLpeIlwdiCxZjDoeY1idiCNWUiyNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOC5zMEexPEDPxE1w	NVr6dJNlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
CP50-MEL-B	NE\ndZFIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	NG\Bb2xKdmirYnn0bY9vKG:oIHj1cYFvKEOSNUCtUWVNNUJiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OCB;IECuNVI4QTRizszNMi=>	NX3tWGM6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
MEL-HO	Mn71S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	NETOb4xKdmirYnn0bY9vKG:oIHj1cYFvKE2HTD3IU{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOC5zM{i4OEDPxE1w	M{fFTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
EoL-1-cell	MWPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	M3fEcmlvcGmkaYTpc44hd2ZiaIXtZY4hTW:OLUGtZ4VtdCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxKD1iMD6xOFQ4PiEQvF2u	Mm\0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
DOK	M2PYfWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	MX7Jcohq[mm2aX;uJI9nKGi3bXHuJGRQUyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxKD1iMD6xOFcxQCEQvF2u	NH3OfZg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
SH-4	NFTwV3pIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	M1f3OGlvcGmkaYTpc44hd2ZiaIXtZY4hW0hvNDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gNE4yPjZ2ODFOwG0v	NWrCZZJLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
BPH-1	MoPVS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	MYLJcohq[mm2aX;uJI9nKGi3bXHuJGJRUC1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTCwMlE5OjNzIN88UU4>	MnPwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
HuP-T4	NVjQV255T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	NXXiR\|dCUW6qaXLpeIlwdiCxZjDoeY1idiCKdWCtWFQh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDBwMUm1N\|Ih\|ryPLh?=	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
KU812	MkG2S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	Mn\STY5pcWKrdHnvckBw\iCqdX3hckBMXThzMjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gNE4zOTF4ODFOwG0v	NWPE[mh{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
A549	NW[zT2lxT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	NWfqZ5J{UW6qaXLpeIlwdiCxZjDoeY1idiCDNUS5JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAxNjJzNEGzJO69VS5?	M1TxTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
HTC-C3	NYnydWE6T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	MmTsTY5pcWKrdHnvckBw\iCqdX3hckBJXENvQ{OgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFAvOjF2NkGg{txONg>?	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
A101D	NFPLT2hIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	MXHJcohq[mm2aX;uJI9nKGi3bXHuJGEyODGGIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTCwMlI1ODN\|IN88UU4>	MmHWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
ONS-76	NWDKbVg{T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	NUi5dW1bUW6qaXLpeIlwdiCxZjDoeY1idiCRTmOtO\|Yh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDBwMkS0OVMh\|ryPLh?=	M{XnXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
RKO	NWfiO4V[T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	M1\CbWlvcGmkaYTpc44hd2ZiaIXtZY4hWkuRIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTCwMlI1QDN6IN88UU4>	MlzJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
WM-115	MoXXS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	NVzYTmZ6UW6qaXLpeIlwdiCxZjDoeY1idiCZTT2xNVUh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDBwMk[3OVQh\|ryPLh?=	MlvoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
HCC2998	NX\6O2ttT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	MYLJcohq[mm2aX;uJI9nKGi3bXHuJGhESzJ7OUigZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFAvOjZ7MEeg{txONg>?	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
C2BBe1	MXLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	M1LmcWlvcGmkaYTpc44hd2ZiaIXtZY4hSzKEQnWxJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAxNjJ5MkW5JO69VS5?	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
RVH-421	MXLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	NHfiWHRKdmirYnn0bY9vKG:oIHj1cYFvKFKYSD20NlEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDBwMke5N\|kh\|ryPLh?=	MmmzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
H-EMC-SS	MVXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	NEX2WZRKdmirYnn0bY9vKG:oIHj1cYFvKEhvRV3DMXNUKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSByLkK5NFk6KM7:TT6=	M2naXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
ML-2	MVXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	NFexUYxKdmirYnn0bY9vKG:oIHj1cYFvKE2OLUKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFAvOjl\|NkOg{txONg>?	NWHYVIg{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
SW620	NYfHXYY1T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	Mlu3TY5pcWKrdHnvckBw\iCqdX3hckBUXzZ{MDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gNE4{ODJ{IN88UU4>	NXT1bG1WRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
UACC-257	MnPpS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	NX\NZZNOUW6qaXLpeIlwdiCxZjDoeY1idiCXQVPDMVI2PyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxKD1iMD6zNlE5PCEQvF2u	MmjUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
AsPC-1	M1TPTGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	MknETY5pcWKrdHnvckBw\iCqdX3hckBCe1CFLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFAvOzJ2M{mg{txONg>?	NIXxb2M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
CAL-39	MXLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	NYGwZXk1UW6qaXLpeIlwdiCxZjDoeY1idiCFQVytN\|kh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDBwM{OyNlYh\|ryPLh?=	NVXWZZlkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
COLO-679	NV3KcJZPT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	NWDMfnZGUW6qaXLpeIlwdiCxZjDoeY1idiCFT1zPMVY4QSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxKD1iMD6zOFEyQSEQvF2u	NF;DXG49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
NCI-H747	M4[1fWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	NIPSO2hKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3IO\|Q4KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSByLkO1NFk5KM7:TT6=	NIDUSWQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
NCI-H1437	M2T6eGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	MXXJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KMUSzO{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOC5\|NUK4OUDPxE1w	Mm\vQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
PSN1	MYjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	MUjJcohq[mm2aX;uJI9nKGi3bXHuJHBUVjFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OCB;IECuN\|Y3ODlizszNMi=>	NIrNWVE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
NKM-1	NYDadFdxT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	M4LIfGlvcGmkaYTpc44hd2ZiaIXtZY4hVkuPLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFAvOzh3ODFOwG0v	NH7yZ3I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
MZ2-MEL	NHj2eYxIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	NXTX[5NuUW6qaXLpeIlwdiCxZjDoeY1idiCPWkKtUWVNKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSByLkO5OFM4KM7:TT6=	NEi5T3o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
SK-MEL-2	NIfTS\|VIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	NH\EdVVKdmirYnn0bY9vKG:oIHj1cYFvKFONLV3FUE0zKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSByLkSwOVA3KM7:TT6=	NH\RT\|I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
LAMA-84	MVLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	M3zFbWlvcGmkaYTpc44hd2ZiaIXtZY4hVEGPQT24OEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOC52NU[yNkDPxE1w	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
U-266	NIPaU3RIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	MWDJcohq[mm2aX;uJI9nKGi3bXHuJHUuOjZ4IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTCwMlQ5Pzd2IN88UU4>	NVnnbGpkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
RCM-1	MV3Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	MVfJcohq[mm2aX;uJI9nKGi3bXHuJHJEVS1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTCwMlQ6Ozh3IN88UU4>	MkX2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
EM-2	Ml7xS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	MUTJcohq[mm2aX;uJI9nKGi3bXHuJGVONTJiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OCB;IECuOVEyPzVizszNMi=>	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
Mewo	NEjNUXZIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	Mny5TY5pcWKrdHnvckBw\iCqdX3hckBO\XexIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTCwMlUzOTBzIN88UU4>	NY\3TmpJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
COLO-741	M{TFVWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	Mn31TY5pcWKrdHnvckBw\iCqdX3hckBEV0yRLUe0NUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOC53M{GxPUDPxE1w	M3T2XlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
ACN	M{jPTWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	NGTPdHJKdmirYnn0bY9vKG:oIHj1cYFvKEGFTjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gNE42PjZ7IN88UU4>	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
MV-4-11	NWfsUI44T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	MVPJcohq[mm2aX;uJI9nKGi3bXHuJG1XNTRvMUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFAvPTd3NEOg{txONg>?	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
SW780	Ml\WS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	NIPjWWFKdmirYnn0bY9vKG:oIHj1cYFvKFOZN{iwJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAxNjZ4NkO0JO69VS5?	MnrPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
JVM-3	MY\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	NFr4[4ZKdmirYnn0bY9vKG:oIHj1cYFvKEqYTT2zJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAxNjdyME[g{txONg>?	Mli4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
RPMI-8226	MWXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	MVTJcohq[mm2aX;uJI9nKGi3bXHuJHJRVUlvOEKyOkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOC55NDFOwG0v	M3TJUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
HO-1-N-1	NIfyZYNIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	NGS3RXBKdmirYnn0bY9vKG:oIHj1cYFvKEiRLUGtUk0yKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSByLke0NFUzKM7:TT6=	NVzOWXBLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
BV-173	Ml\RS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	NUnJ[HhUUW6qaXLpeIlwdiCxZjDoeY1idiCEVj2xO\|Mh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDBwN{S4NFIh\|ryPLh?=	M{fUcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
NCI-H2291	MWDHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	NILxNoZKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3INlI6OSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxKD1iMD63OlE4OyEQvF2u	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
SK-MEL-30	M3v6OWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	MnG1TY5pcWKrdHnvckBw\iCqdX3hckBUUy2PRVytN\|Ah[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDBwN{ixO\|Eh\|ryPLh?=	MkHPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
LB2241-RCC	MW\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	MmHFTY5pcWKrdHnvckBw\iCqdX3hckBNSjJ{NEGtVmNEKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSByLke4PVkyKM7:TT6=	M1noRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
LOXIMVI	M4nwZ2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7	M1X6eWlvcGmkaYTpc44hd2ZiaIXtZY4hVE:[SV3WTUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOC56NUi1OEDPxE1w	M4nS[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
HT-29	MYTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	M2T2OGlvcGmkaYTpc44hd2ZiaIXtZY4hUFRvMkmgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFAvQDd\|MUmg{txONg>?	Ml7tQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
KG-1	MoS5S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	M4\sOmlvcGmkaYTpc44hd2ZiaIXtZY4hU0dvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gNE45QTV2NzFOwG0v	NUH2NndHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
SW954	MoroS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	MUnJcohq[mm2aX;uJI9nKGi3bXHuJHNYQTV2IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTCwMlg6PjR3IN88UU4>	Mo\0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
MIA-PaCa-2	M1jZT2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7	NX3pZmNtUW6qaXLpeIlwdiCxZjDoeY1idiCPSVGtVIFE[S1{IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTCwMlg6PzZ6IN88UU4>	NWCxcVJwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
HCE-T	NGPzbINIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	MWfJcohq[mm2aX;uJI9nKGi3bXHuJGhETS2WIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTCwMlk4OTNzIN88UU4>	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
HN	NWLHNGJGT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	NEC1ZZhKdmirYnn0bY9vKG:oIHj1cYFvKEiQIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTCxMlAxOjV5IN88UU4>	M2nCelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
LCLC-97TM1	M{fVVWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	MkfvTY5pcWKrdHnvckBw\iCqdX3hckBNS0yFLUm3WG0yKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSBzLkCzNVkyKM7:TT6=	Ml;lQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
NB69	MVPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	NGLieXBKdmirYnn0bY9vKG:oIHj1cYFvKE6ENkmgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFEvODV\|OTFOwG0v	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
LoVo	NVewW3lET3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	Mnz3TY5pcWKrdHnvckBw\iCqdX3hckBNd1[xIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTCxMlA3OjNzIN88UU4>	M2L6TFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
HCT-116	M33Id2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7	NVjYWI41UW6qaXLpeIlwdiCxZjDoeY1idiCKQ2StNVE3KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSBzLkC2OFMyKM7:TT6=	M4TiT\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
AGS	MkfLS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	NXzoemc2UW6qaXLpeIlwdiCxZjDoeY1idiCDR2OgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFEvOTF6M{Gg{txONg>?	M2HYcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
NCI-H292	MXjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	MmO1TY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEK5NkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOS5zMUm5JO69VS5?	M3\RPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
P12-ICHIKAWA	M{j4cWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	Mn;YTY5pcWKrdHnvckBw\iCqdX3hckBROTJvSVPITWtCX0FiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OCB;IEGuNVU5QTlizszNMi=>	NHvCOXg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
D-263MG	NUXQUnpqT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	MVHJcohq[mm2aX;uJI9nKGi3bXHuJGQuOjZ\|TVegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFEvOThyOUSg{txONg>?	M1rpOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
COLO-792	Mm\FS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	NVvkdWJ2UW6qaXLpeIlwdiCxZjDoeY1idiCFT1zPMVc6OiClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxKD1iMT6xPFY{KM7:TT6=	MnH5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
HSC-3	NVvZNXFwT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	NVnG[INIUW6qaXLpeIlwdiCxZjDoeY1idiCKU1OtN{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOS5zOEiyN{DPxE1w	NUO3[21jRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
NUGC-3	NGHPcpdIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	NWjFSm9QUW6qaXLpeIlwdiCxZjDoeY1idiCQVVfDMVMh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDFwMkCzO\|kh\|ryPLh?=	NXvEeWdiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
SW872	NGmxVVRIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	NHLSWJZKdmirYnn0bY9vKG:oIHj1cYFvKFOZOEeyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAyNjJ4OEW1JO69VS5?	MkjlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
HuCCT1	NVLZU2d5T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	NULZU3g4UW6qaXLpeIlwdiCxZjDoeY1idiCKdVPDWFEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDFwMkm5OkDPxE1w	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
QIMR-WIL	NGLkNGhIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	M2X3OWlvcGmkaYTpc44hd2ZiaIXtZY4hWUmPUj3XTWwh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDFwM{SzPFQh\|ryPLh?=	M1W5b\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
NCI-H2087	MUPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	NH;NSWhKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3INlA5PyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxKD1iMT6zO\|UyKM7:TT6=	NYrVbFgxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
LS-513	NELhcIpIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	MoXKTY5pcWKrdHnvckBw\iCqdX3hckBNWy13MUOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFEvPDJzOUGg{txONg>?	NGjFVnc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
CAL-54	MXnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	M{\hPGlvcGmkaYTpc44hd2ZiaIXtZY4hS0GOLUW0JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAyNjR7M{G0JO69VS5?	NHzCUWQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
A204	NYLiNot2T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	NVrndVJkUW6qaXLpeIlwdiCxZjDoeY1idiCDMkC0JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAyNjVzNk[3JO69VS5?	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
CAL-62	MXPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	M{K5O2lvcGmkaYTpc44hd2ZiaIXtZY4hS0GOLU[yJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAyNjV{MkmyJO69VS5?	NIjCZlY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
CAL-33	NU\6NZFYT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	NWS1O3N2UW6qaXLpeIlwdiCxZjDoeY1idiCFQVytN\|Mh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDFwNUS2PVQh\|ryPLh?=	MkXUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
COLO-678	MXTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	MUPJcohq[mm2aX;uJI9nKGi3bXHuJGNQVE9vNke4JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAyNjZ{M{iyJO69VS5?	MkLzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
MEG-01	MoLOS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	M{WyemlvcGmkaYTpc44hd2ZiaIXtZY4hVUWJLUCxJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAyNjZ{OUW5JO69VS5?	NFjlWpE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
HAL-01	MXLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	M2H3UGlvcGmkaYTpc44hd2ZiaIXtZY4hUEGOLUCxJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAyNjZ7NUeg{txONg>?	MlvSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
OAW-28	NH\YUoNIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	M3W1SWlvcGmkaYTpc44hd2ZiaIXtZY4hV0GZLUK4JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAyNjd2M{m3JO69VS5?	NFrhXHE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
NCI-SNU-1	MYPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	MmL5TY5pcWKrdHnvckBw\iCqdX3hckBPS0lvU17VMVEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDFwN{eyOFMh\|ryPLh?=	MmXNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
BHY	MX7Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	NFnURlJKdmirYnn0bY9vKG:oIHj1cYFvKEKKWTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gNU45OTB\|NDFOwG0v	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
EGI-1	MlHnS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	NWD6[FBxUW6qaXLpeIlwdiCxZjDoeY1idiCHR1mtNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOS56MkiyJO69VS5?	MmnvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
BB65-RCC	NGDS[XpIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	NGTCOIJKdmirYnn0bY9vKG:oIHj1cYFvKEKENkWtVmNEKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSBzLkizPFU2KM7:TT6=	MmS1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
GAK	M1X2Umdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	NF3ybohKdmirYnn0bY9vKG:oIHj1cYFvKEeDSzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gNU46ODR5NTFOwG0v	NV;EeHBsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
SK-MEL-3	MUHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	MXXJcohq[mm2aX;uJI9nKGi3bXHuJHNMNU2HTD2zJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAyNjl3MEe3JO69VS5?	M1X4bVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
KARPAS-45	MYHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	Mn;0TY5pcWKrdHnvckBw\iCqdX3hckBMSVKSQWOtOFUh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDJwMEiyOFgh\|ryPLh?=	MoHFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
BCPAP	M{Pofmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	MXzJcohq[mm2aX;uJI9nKGi3bXHuJGJEWEGSIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTCyMlEzPzRizszNMi=>	Moq0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
RT-112	MmP0S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	NXXYb3pkUW6qaXLpeIlwdiCxZjDoeY1idiCUVD2xNVIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDJwMk[wOFYh\|ryPLh?=	M2fqdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
SK-HEP-1	Mk\xS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	MV3Jcohq[mm2aX;uJI9nKGi3bXHuJHNMNUiHUD2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAzNjJ7MES4JO69VS5?	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
Ca9-22	MmDxS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	Mm[zTY5pcWKrdHnvckBw\iCqdX3hckBE[TlvMkKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFIvOzd4Nkeg{txONg>?	MkfmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
OS-RC-2	NEnjNWJIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	MmC0TY5pcWKrdHnvckBw\iCqdX3hckBQWy2UQz2yJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAzNjRyM{O3JO69VS5?	NITneIE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
BFTC-905	NEPIc4NIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	NH7lc25KdmirYnn0bY9vKG:oIHj1cYFvKEKIVFOtPVA2KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSB{LkSyN\|EzKM7:TT6=	Mln6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
HT-1080	MWnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	MYTJcohq[mm2aX;uJI9nKGi3bXHuJGhVNTFyOECgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFIvPDNyMTFOwG0v	Ml7nQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
HCC2218	MXPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	NU\ObHNpUW6qaXLpeIlwdiCxZjDoeY1idiCKQ1OyNlE5KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSB{LkS4OFg4KM7:TT6=	Mki1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
KM12	NUnhSXpJT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	NXnJdnZoUW6qaXLpeIlwdiCxZjDoeY1idiCNTUGyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAzNjV\|OU[xJO69VS5?	NXvWT4c{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
NB5	NH7sRo1Iem:5dHigbY5pcWKrdHnvckBie3OjeR?=	NEnSW5RKdmirYnn0bY9vKG:oIHj1cYFvKE6ENTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gNk42PjZ2MTFOwG0v	NV:yNnRoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
BB30-HNC	NIf2SJJIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	MnP5TY5pcWKrdHnvckBw\iCqdX3hckBDSjNyLVjOR{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOi55MUK5N{DPxE1w	NH\FTWs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
NCI-H460	NIHVcGdIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	NXj2SHZJUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFQ3OCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxKD1iMj64NFI4PCEQvF2u	NUX4VW93RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
LAN-6	NFrRO4hIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	M1PES2lvcGmkaYTpc44hd2ZiaIXtZY4hVEGQLU[gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFIvQDJ6Nkeg{txONg>?	Mnm3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
EW-3	MVPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	NEf4TlJKdmirYnn0bY9vKG:oIHj1cYFvKEWZLUOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFIvQTJ3MEWg{txONg>?	M2XUVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
CAL-27	M3vxeWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	Ml3kTY5pcWKrdHnvckBw\iCqdX3hckBESUxvMkegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFMvODZzMUig{txONg>?	M2Hj[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
COR-L105	NEO2bGVIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	MkG3TY5pcWKrdHnvckBw\iCqdX3hckBEV1JvTEGwOUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOy5zM{S2NkDPxE1w	M1n4eFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
EFO-21	MmTLS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	M3n2TmlvcGmkaYTpc44hd2ZiaIXtZY4hTU[RLUKxJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUA{NjF7MkK2JO69VS5?	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
MZ1-PC	NUjSb2hxT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	NIfzNVRKdmirYnn0bY9vKG:oIHj1cYFvKE2cMT3QR{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOy5\|MU[wOUDPxE1w	NIjzV2c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
EFO-27	NGfHS5BIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	MVTJcohq[mm2aX;uJI9nKGi3bXHuJGVHVy1{NzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gN{4{OjZzMjFOwG0v	NUXCWFlERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
HPAF-II	NGnoOmFIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	NV76c2huUW6qaXLpeIlwdiCxZjDoeY1idiCKUFHGMWlKKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSB\|LkOzO\|I6KM7:TT6=	NH3qWY89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
KU-19-19	M4nDVGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	NWjC[WFkUW6qaXLpeIlwdiCxZjDoeY1idiCNVT2xPU0yQSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxKD1iMz60NVk2OSEQvF2u	NGi5[Hc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
NCI-SNU-5	NXiw[I42T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	NIjVUYpKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3TUnUuPSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxKD1iMz62NVQ1QSEQvF2u	MorrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
LS-123	NV7MOphzT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	NXryR4p7UW6qaXLpeIlwdiCxZjDoeY1idiCOUz2xNlMh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDNwNkG4N\|Eh\|ryPLh?=	NXrldWtyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
769-P	NFe0W5ZIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	MYrJcohq[mm2aX;uJI9nKGi3bXHuJFc3QS2SIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTCzMlc1OjZizszNMi=>	MoXHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
SJSA-1	MmfIS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	MVPJcohq[mm2aX;uJI9nKGi3bXHuJHNLW0FvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gN{44QDF2NjFOwG0v	M{XHXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
SK-LU-1	M4TJNGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	MnvGTY5pcWKrdHnvckBw\iCqdX3hckBUUy2OVT2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUA{Njh4MkOxJO69VS5?	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
A3-KAW	M{m3[2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7	M{XZSGlvcGmkaYTpc44hd2ZiaIXtZY4hSTNvS1HXJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUA{NjlzMEW1JO69VS5?	Mo\3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
LB996-RCC	MnTNS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	MXXJcohq[mm2aX;uJI9nKGi3bXHuJGxDQTl4LWLDR{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOy57NUC0N{DPxE1w	M{PSNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
SN12C	NXnsdJA4T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	MYfJcohq[mm2aX;uJI9nKGi3bXHuJHNPOTKFIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTCzMlk2PTd\|IN88UU4>	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
COR-L23	NX;JWJcxT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	NFO2XmtKdmirYnn0bY9vKG:oIHj1cYFvKEORUj3MNlMh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDNwOUW2Olkh\|ryPLh?=	NVf5RllMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
VM-CUB-1	MmO5S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	MUnJcohq[mm2aX;uJI9nKGi3bXHuJHZONUOXQj2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUA{Njl4OUOxJO69VS5?	NWDQT\|NnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
RXF393	NXzvVFRGT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	MUnJcohq[mm2aX;uJI9nKGi3bXHuJHJZTjN7MzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gOE4xOTV7MTFOwG0v	MofQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
MOLT-13	MY\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	NW\JSmtkUW6qaXLpeIlwdiCxZjDoeY1idiCPT1zUMVE{KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSB2LkCzOFE6KM7:TT6=	Mlq2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
GCT	NULvc4xqT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	NVy0TlhIUW6qaXLpeIlwdiCxZjDoeY1idiCJQ2SgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFQvOTB2NEKg{txONg>?	NGK4W3U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
SW1990	MXHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	M1S2cmlvcGmkaYTpc44hd2ZiaIXtZY4hW1dzOUmwJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUA1NjF4NkKyJO69VS5?	NFvNbJM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
RD	MX7Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	MmPITY5pcWKrdHnvckBw\iCqdX3hckBTTCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxKD1iND6xPVE{QCEQvF2u	MmTLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
HOP-92	NHfLUVhIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	M1T0SGlvcGmkaYTpc44hd2ZiaIXtZY4hUE:SLUmyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUA1NjJyMEmzJO69VS5?	MkPoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
ME-180	NITPc2RIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	NUjT[WxGUW6qaXLpeIlwdiCxZjDoeY1idiCPRT2xPFAh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDRwMkW4OVkh\|ryPLh?=	NYPXSI0xRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
MZ7-mel	M1X1NWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	NVfMUnZ5UW6qaXLpeIlwdiCxZjDoeY1idiCPWketcYVtKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSB2LkS1NlY2KM7:TT6=	NXzHZ5M4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
CAKI-1	NHjXb2NIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	MUDJcohq[mm2aX;uJI9nKGi3bXHuJGNCU0lvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gOE41PjB3NzFOwG0v	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
YKG-1	M3H4R2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7	NYPMeHBwUW6qaXLpeIlwdiCxZjDoeY1idiC\S1etNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hPC53M{SyNUDPxE1w	NW\CUpd{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
PANC-03-27	MWfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	M1n0dGlvcGmkaYTpc44hd2ZiaIXtZY4hWEGQQz2wN{0zPyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxKD1iND61N\|kzQSEQvF2u	NV;SSHgzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
A4-Fuk	NVm0VlF5T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	NWXH[nIxUW6qaXLpeIlwdiCxZjDoeY1idiCDND3GeYsh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDRwNUSyNFIh\|ryPLh?=	NFrkR5A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
NCI-H441	NGfvWXdIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	M1ns[2lvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVi0OFEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDRwNU[zOFIh\|ryPLh?=	NV;qTVZMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
BxPC-3	NWLNWmR6T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	NV3USIxtUW6qaXLpeIlwdiCxZjDoeY1idiCEeGDDMVMh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDRwNkW5O\|Yh\|ryPLh?=	NIS1[4U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
ES3	MkHES5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	NHH2eW9KdmirYnn0bY9vKG:oIHj1cYFvKEWVMzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gOE43QTF5MzFOwG0v	NXnpRm1ERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
GP5d	MV;Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	NWTWS3Y6UW6qaXLpeIlwdiCxZjDoeY1idiCJUEXkJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUA1Njd6NUWzJO69VS5?	NEXKUJQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
CAL-85-1	M2HPemdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	NWfPOZFFUW6qaXLpeIlwdiCxZjDoeY1idiCFQVytPFUuOSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxKD1iND63PVQzKM7:TT6=	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
EPLC-272H	MV7Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	MX;Jcohq[mm2aX;uJI9nKGi3bXHuJGVRVENvMkeyTEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hPC56MU[5PEDPxE1w	NWW2fnIzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
HuP-T3	M{fTTGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	M3nBfmlvcGmkaYTpc44hd2ZiaIXtZY4hUHWSLWSzJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUA1Njh{NEC4JO69VS5?	NV7kNVhURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
SW1710	NXrCUFBwT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	M1XZd2lvcGmkaYTpc44hd2ZiaIXtZY4hW1dzN{GwJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUA2NjB\|NUS5JO69VS5?	Mo\EQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
TE-8	MX3Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	NHXmcFdKdmirYnn0bY9vKG:oIHj1cYFvKFSHLUigZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFUvODZ7MUGg{txONg>?	MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
TE-12	MkKzS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	NIrxeo5KdmirYnn0bY9vKG:oIHj1cYFvKFSHLUGyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUA2NjF\|N{CzJO69VS5?	Mn3mQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
NCI-H1573	MmTlS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	NXW2OWNOUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFE2PzNiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OCB;IEWuNlczOzhizszNMi=>	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
SW1417	NIjjUWtIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	MXLJcohq[mm2aX;uJI9nKGi3bXHuJHNYOTRzNzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gOU4zPzN7ODFOwG0v	NF7hN\|M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
CHL-1	NHHIbYdIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	NIDKSFBKdmirYnn0bY9vKG:oIHj1cYFvKEOKTD2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUA2NjNzOUmg{txONg>?	M3nxeVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
Calu-6	NWrk[\|c3T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	M3j6dWlvcGmkaYTpc44hd2ZiaIXtZY4hS2GudT22JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUA2NjR{OUK3JO69VS5?	NETqdoc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
MDA-MB-231	NEPj[GdIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	M2C1PWlvcGmkaYTpc44hd2ZiaIXtZY4hVUSDLV3CMVI{OSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxKD1iNT61OlUzOyEQvF2u	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
SCC-25	Ml3YS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	MUTJcohq[mm2aX;uJI9nKGi3bXHuJHNESy1{NTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gOU46PzF{MTFOwG0v	NV3STmZIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
639-V	MXXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	NXzkfHpRUW6qaXLpeIlwdiCxZjDoeY1idiB4M{mtWkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hPi5zMkmzN{DPxE1w	M4LJ[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
D-502MG	M4H6dmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	NGTaRnJKdmirYnn0bY9vKG:oIHj1cYFvKERvNUCyUWch[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDZwMUe2OVkh\|ryPLh?=	NFvEN5Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
PANC-10-05	MVTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	MmfTTY5pcWKrdHnvckBw\iCqdX3hckBRSU6FLUGwMVA2KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSB4LkKwNVgyKM7:TT6=	NIjPU\|U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
Ramos-2G6-4C10	Mnr4S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	MXPJcohq[mm2aX;uJI9nKGi3bXHuJHJidW:\|LULHOk01SzFyIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTC2MlI4ODl2IN88UU4>	NFzS[XM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
NB10	MWrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	NYewVIxHUW6qaXLpeIlwdiCxZjDoeY1idiCQQkGwJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUA3NjN{NUOzJO69VS5?	NGP4UFQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
MSTO-211H	MXfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	NUG0Z\|FNUW6qaXLpeIlwdiCxZjDoeY1idiCPU2TPMVIyOUhiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OCB;IE[uOFAxQCEQvF2u	M3e2e\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
NCI-H1651	M{\pfWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	NGXwPGFKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3INVY2OSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxKD1iNj62OVMzQCEQvF2u	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
697	Ml[zS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	NIDXUIJKdmirYnn0bY9vKG:oIHj1cYFvKDZ7NzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gOk43PzN7NzFOwG0v	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
HCC70	M2Xke2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7	MVLJcohq[mm2aX;uJI9nKGi3bXHuJGhESzdyIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTC2MlY5QDZ3IN88UU4>	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
SW1116	MWHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	M3rqfWlvcGmkaYTpc44hd2ZiaIXtZY4hW1dzMUG2JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUA3NjhzMkm3JO69VS5?	Mlj5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
SK-MES-1	NVr1XXg3T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	M4TZfmlvcGmkaYTpc44hd2ZiaIXtZY4hW0tvTVXTMVEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDZwOES4PEDPxE1w	M{Hyb\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
GCIY	MkXWS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	MknOTY5pcWKrdHnvckBw\iCqdX3hckBIS0m\IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTC2MlkyQTZ{IN88UU4>	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
GMS-10	M17vSWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	NXe3U3k6UW6qaXLpeIlwdiCxZjDoeY1idiCJTWOtNVAh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDdwMEe3OVUh\|ryPLh?=	M1rqUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
NCI-H1092	NULIR29IT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	Mki2TY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEGwPVIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDdwMUWzN\|Qh\|ryPLh?=	NYTuVJJxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
CFPAC-1	NGf1WlRIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	M1zpOWlvcGmkaYTpc44hd2ZiaIXtZY4hS0[SQVOtNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hPy5{MkGwNUDPxE1w	M3TRPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
TK10	NF;Q[VZIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	MXLJcohq[mm2aX;uJI9nKGi3bXHuJHRMOTBiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OCB;IEeuN\|U2QDdizszNMi=>	NV\0XIE4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
FADU	NX:2V5hPT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	NF\6copKdmirYnn0bY9vKG:oIHj1cYFvKE[DRGWgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFcvPTB7MzFOwG0v	MlnDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
8305C	MU\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	NXiwNHFTUW6qaXLpeIlwdiCxZjDoeY1idiB6M{C1R{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hPy56NUO1OUDPxE1w	Mo\ZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
DK-MG	M4rPTWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	NWHtUmI{UW6qaXLpeIlwdiCxZjDoeY1idiCGSz3NS{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hPy57NEmzO{DPxE1w	NE\yRVc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
BFTC-909	Ml34S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	MUXJcohq[mm2aX;uJI9nKGi3bXHuJGJHXENvOUC5JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUA4Njl5OEO2JO69VS5?	NXuySFNCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
IGR-1	MlPoS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	Mnz3TY5pcWKrdHnvckBw\iCqdX3hckBKT1JvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gPE4yQDB3MTFOwG0v	MkPEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
MDA-MB-361	M4fCfmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	NWPBXmJ1UW6qaXLpeIlwdiCxZjDoeY1idiCPRFGtUWIuOzZzIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTC4MlE5OjRizszNMi=>	NVP2cVZ2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
KYSE-150	NIfS[HRIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	MmLpTY5pcWKrdHnvckBw\iCqdX3hckBMYVOHLUG1NEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hQC5{MUmzO{DPxE1w	M2\WbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
DB	M{TvbWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	NFTGNoFKdmirYnn0bY9vKG:oIHj1cYFvKESEIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTC4MlM3QTB3IN88UU4>	NEH0XHI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
NH-12	MVnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	MkPRTY5pcWKrdHnvckBw\iCqdX3hckBPUC1zMjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gPE41Ojd\|NjFOwG0v	MoO4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
CTV-1	NUHsV5NGT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	MlvETY5pcWKrdHnvckBw\iCqdX3hckBEXFZvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gPE41OzN\|NzFOwG0v	M3f2U\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
A498	MkS3S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	NYj0dm9ZUW6qaXLpeIlwdiCxZjDoeY1idiCDNEm4JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUA5Njd6NEe1JO69VS5?	M1fsZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
LS-1034	NE\sWWNIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	MmD0TY5pcWKrdHnvckBw\iCqdX3hckBNWy1zMEO0JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUA5Njl4NE[0JO69VS5?	MmrGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
FTC-133	NILXXlhIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	M4DUTGlvcGmkaYTpc44hd2ZiaIXtZY4hTlSFLUGzN{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hQC57OES1PUDPxE1w	Mn3PQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
TGBC11TKB	M1XOcGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	NVTidm82UW6qaXLpeIlwdiCxZjDoeY1idiCWR1LDNVFVU0JiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OCB;IEmuNVA5OzZizszNMi=>	MkO0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
SK-MEL-1	NWe1[XZvT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	MkfWTY5pcWKrdHnvckBw\iCqdX3hckBUUy2PRVytNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hQS5zOUGzOkDPxE1w	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
RPMI-7951	NWnFPXJIT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	NY\IXm1lUW6qaXLpeIlwdiCxZjDoeY1idiCUUF3JMVc6PTFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OCB;IEmuNlUzODFizszNMi=>	NYXZWIM{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
GT3TKB	M1vXWGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	M13DbWlvcGmkaYTpc44hd2ZiaIXtZY4hT1R\|VFvCJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUA6NjN5NECzJO69VS5?	NXvQZ2ZVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
SW962	NU\heZZGT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	NYCy[\|d[UW6qaXLpeIlwdiCxZjDoeY1idiCVV{m2NkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hQS53MkOyOUDPxE1w	NUnpSmpVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
T-24	M4TZOmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	M334U2lvcGmkaYTpc44hd2ZiaIXtZY4hXC1{NDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gPU43PThyNzFOwG0v	NUXqOYNRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
DBTRG-05MG	M2HRe2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7	NEHsTmhKdmirYnn0bY9vKG:oIHj1cYFvKESEVGLHMVA2VUdiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OCB;IEmuO\|U3PjZizszNMi=>	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
G-401	MUHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	NGCyU3pKdmirYnn0bY9vKG:oIHj1cYFvKEdvNECxJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAyOC5yN{O5JO69VS5?	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
RS4-11	M3XUeGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	MmnaTY5pcWKrdHnvckBw\iCqdX3hckBTWzRvMUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFExNjJ5OUGg{txONg>?	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
KGN	M4GwU2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7	MoqwTY5pcWKrdHnvckBw\iCqdX3hckBMT05iY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OCB;IEGwMlQxPDZizszNMi=>	M2H5WFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
786-0	M1vZ[Wdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	NV;0TVNiUW6qaXLpeIlwdiCxZjDoeY1idiB5OE[tNEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOTBwNEG2OkDPxE1w	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
EW-18	M3v5OGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	MYTJcohq[mm2aX;uJI9nKGi3bXHuJGVYNTF6IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTCxNE41OzZ4IN88UU4>	MkPaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
DEL	MYfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	NGjzWm9KdmirYnn0bY9vKG:oIHj1cYFvKESHTDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gNVAvPTR3IN88UU4>	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
HuH-7	MWnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	Ml3JTY5pcWKrdHnvckBw\iCqdX3hckBJfUhvNzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gNVAvPTdyNTFOwG0v	Ml6zQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
MG-63	Mkm1S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	MVrJcohq[mm2aX;uJI9nKGi3bXHuJG1INTZ\|IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTCxNE44OzN\|IN88UU4>	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
A253	NIjjdlNIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	MYHJcohq[mm2aX;uJI9nKGi3bXHuJGEzPTNiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OCB;IEGwMlc6ODJizszNMi=>	NEXwXmQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
TGW	M3zyfWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	MkTqTY5pcWKrdHnvckBw\iCqdX3hckBVT1diY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OCB;IEGwMlc6OzdizszNMi=>	NEDBOlI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
HH	MljFS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	MULJcohq[mm2aX;uJI9nKGi3bXHuJGhJKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSBzMD64NFYzKM7:TT6=	M{LOVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
LS-411N	NXz4Z4VmT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	NXH4dVZ7UW6qaXLpeIlwdiCxZjDoeY1idiCOUz20NVFPKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSBzMD64NlQ1KM7:TT6=	M4f3[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
NCI-H2347	NIrCXlRIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	NEG0OoFKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3INlM1PyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxKD1iMUCuPFQ{PyEQvF2u	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
LU-65	NIjDN\|ZIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	M1LhcGlvcGmkaYTpc44hd2ZiaIXtZY4hVFVvNkWgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFExNjl{Mk[g{txONg>?	MlzRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
TE-11	M1vodmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	NHviVHdKdmirYnn0bY9vKG:oIHj1cYFvKFSHLUGxJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAyOS5yMkWg{txONg>?	MnnMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
SBC-1	MUPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	M1f4dGlvcGmkaYTpc44hd2ZiaIXtZY4hW0KFLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFEyNjFyM{Kg{txONg>?	Mm\VQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
TGBC24TKB	M1j1RWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	NHXiUVZKdmirYnn0bY9vKG:oIHj1cYFvKFSJQlOyOHRMSiClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxKD1iMUGuNVE5KM7:TT6=	NF\RNm89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
ECC10	NWjNcYU5T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	MkezTY5pcWKrdHnvckBw\iCqdX3hckBGS0NzMDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gNVEvOjJ6MzFOwG0v	Mn:wQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
GR-ST	MoPZS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	MofETY5pcWKrdHnvckBw\iCqdX3hckBIWi2VVDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gNVEvOjZ6IN88UU4>	MljwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
NCI-H720	MoLRS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	MkPHTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEeyNEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOTFwM{m3O{DPxE1w	M3XyVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
VA-ES-BJ	NY[we3pjT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	M1L5b2lvcGmkaYTpc44hd2ZiaIXtZY4hXkFvRWOtRmoh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDFzLkW1NVMh\|ryPLh?=	Mn76QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
MOLT-16	MWfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	NYDmc5V6UW6qaXLpeIlwdiCxZjDoeY1idiCPT1zUMVE3KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSBzMj6xNVYyKM7:TT6=	NX\nU5J2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
KYSE-140	MYXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	NEXYTlRKdmirYnn0bY9vKG:oIHj1cYFvKEu\U1WtNVQxKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSBzMj6xOVk3KM7:TT6=	MlnoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
SCC-4	MYHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	M1fub2lvcGmkaYTpc44hd2ZiaIXtZY4hW0OFLUSgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFEzNjJ2IN88UU4>	Mlu0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
NCI-H1155	MYfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	M4i2fWlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVixNVU2KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSBzMj6zNFE4KM7:TT6=	NVTXdWtHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
OCUB-M	M1rWNGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	NXK0cJRJUW6qaXLpeIlwdiCxZjDoeY1idiCRQ2XCMW0h[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDF{LkOxPFkh\|ryPLh?=	NH3vNI09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
MN-60	NF\4cZpIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	NYXUbFhYUW6qaXLpeIlwdiCxZjDoeY1idiCPTj22NEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOTJwM{ezNkDPxE1w	M1;rRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
RO82-W-1	MV7Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	NX;GUHpCUW6qaXLpeIlwdiCxZjDoeY1idiCUT{iyMXcuOSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxKD1iMUKuN\|g4QSEQvF2u	NITWdYU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
KOSC-2	NGrB[ZdIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	NWGxeGZyUW6qaXLpeIlwdiCxZjDoeY1idiCNT2PDMVIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDF{LkW1NFgh\|ryPLh?=	NU\ZXHg6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
L-363	NF31SVNIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	M4\nNmlvcGmkaYTpc44hd2ZiaIXtZY4hVC1\|NkOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFEzNjV7MkWg{txONg>?	NE\GTGc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
NCI-H661	NIHKVFVIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	M1rRN2lvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVi2OlEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDF{Lki1PFch\|ryPLh?=	NWK1SJVtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
KYSE-450	NWfKN49xT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	Mo\sTY5pcWKrdHnvckBw\iCqdX3hckBMYVOHLUS1NEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOTNwMEO5OkDPxE1w	MoHNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
TI-73	NU\ab\|N2T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	M2LEdWlvcGmkaYTpc44hd2ZiaIXtZY4hXElvN{OgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFE{NjB2NDFOwG0v	Mn3uQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
KNS-81-FD	NWr1V29TT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	NFjEPWVKdmirYnn0bY9vKG:oIHj1cYFvKEuQUz24NU1HTCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxKD1iMUOuNFc1QCEQvF2u	NFHUeo49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
HCC1954	NVrXSIdzT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	NVTJW\|Z1UW6qaXLpeIlwdiCxZjDoeY1idiCKQ1OxPVU1KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSBzMz6yO\|g{KM7:TT6=	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
A427	M4e0VWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	NIDNSoNKdmirYnn0bY9vKG:oIHj1cYFvKEF2MkegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFE{NjZ4OEmg{txONg>?	Mm[1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
MOLT-4	M{fVS2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7	NEDXXYNKdmirYnn0bY9vKG:oIHj1cYFvKE2RTGStOEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOTNwOEWzNUDPxE1w	M4e4R\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
U-118-MG	MmL2S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	MWrJcohq[mm2aX;uJI9nKGi3bXHuJHUuOTF6LV3HJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAyOy56N{CyJO69VS5?	NGXlcow9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
SF126	MnnWS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	NVrieVRTUW6qaXLpeIlwdiCxZjDoeY1idiCVRkGyOkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOTNwOUG2OUDPxE1w	M3LRPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
SF539	NF;aPGFIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	MYnJcohq[mm2aX;uJI9nKGi3bXHuJHNHPTN7IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTCxN{46PDd2IN88UU4>	NWf1V4lZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
Daoy	NHHXdFVIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	NHO1UJRKdmirYnn0bY9vKG:oIHj1cYFvKESjb4mgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFE1NjR7N{mg{txONg>?	M3vBWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
DoTc2-4510	M164cmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	NELSOmRKdmirYnn0bY9vKG:oIHj1cYFvKESxVHOyMVQ2OTBiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OCB;IEG0MlUyPzVizszNMi=>	NUKxUHViRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
TYK-nu	NXnhRWtnT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	MVzJcohq[mm2aX;uJI9nKGi3bXHuJHR[Uy2wdTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gNVQvPTZizszNMi=>	NVTHenRHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
CGTH-W-1	MWHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	M{XROWlvcGmkaYTpc44hd2ZiaIXtZY4hS0eWSD3XMVEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDF2Lki0PFMh\|ryPLh?=	NH[3cFM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
HuO9	MYTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	MUXJcohq[mm2aX;uJI9nKGi3bXHuJGh2VzliY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OCB;IEG1MlA3OyEQvF2u	NUGxfVd5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
EW-16	MoHsS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	NVnacHhxUW6qaXLpeIlwdiCxZjDoeY1idiCHVz2xOkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOTVwMEm0PUDPxE1w	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
NCI-H630	M1PJU2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7	MYDJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KNkOwJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAyPS5zNkGzJO69VS5?	M1:zcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,

研究领域

产品类型